I don't think anyone has shown that diversity plays a role in the efficacy of a probiotic. In fact if you read the abstract of the last paper in this message you will see they warn that "Combining potentially anti-inflammatory and proinflammatory bacteria in the same preparation would be particularly counterproductive and presents the alarming situation where an ill-chosen probiotic species might exacerbate disease." I suspect specific strains of individual species may be more important.
Generally speaking it always the company's responsibility to pay for clinical investigation.
-------------------- STABLE: ♂, IBS-D 50+ years - Science of IBS
Posts
Re: trials
